EGFR and cancer: Exosomes can be internalized by EGFR-mutated cancer cells through lattice-protein-dependent endocytosis, and then encapsulated exosomal wild-type EGFR protein then activates the downstream PI3K/AKT and MAPK signaling pathways and triggers osimertinib resistance (Wu et al., 2021).